Found: 90
Select item for more details and to access through your institution.
Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml).
- Published in:
- Prostate, 2001, v. 47, n. 4, p. 252, doi. 10.1002/pros.1069
- By:
- Publication type:
- Article
Defining the window of opportunity in screening for prostate cancer: Validation of a predictive tumor classification model.
- Published in:
- Prostate, 2001, v. 46, n. 2, p. 154, doi. 10.1002/1097-0045(20010201)46:2<154::AID-PROS1019>3.0.CO;2-1
- By:
- Publication type:
- Article
A standardized method to measure the membranous urethral length (MUL) on MRI of the prostate with high inter- and intra-observer agreement.
- Published in:
- European Radiology, 2023, v. 33, n. 5, p. 3295, doi. 10.1007/s00330-022-09320-2
- By:
- Publication type:
- Article
Comment on Rosenzweig et al. Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates. J. Pers. Med. 2022, 12 , 410.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
- Published in:
- BJU International, 2012, v. 110, n. 8, p. 1169, doi. 10.1111/j.1464-410X.2012.10996.x
- By:
- Publication type:
- Article
Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
- Published in:
- BJU International, 2012, v. 109, n. 2, p. 183, doi. 10.1111/j.1464-410X.2011.10652.x
- By:
- Publication type:
- Article
Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
- Published in:
- BJU International, 2012, v. 109, n. 2, p. 176, doi. 10.1111/j.1464-410X.2011.10651.x
- By:
- Publication type:
- Article
Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5α-reductase.
- Published in:
- BJU International, 2009, v. 104, n. 9, p. 1191, doi. 10.1111/j.1464-410X.2009.08743.x
- By:
- Publication type:
- Article
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
- Published in:
- BJU International, 2009, v. 104, n. 4, p. 438, doi. 10.1111/j.1464-410X.2009.08695.x
- By:
- Publication type:
- Article
Added Clinical Value of <sup>18</sup>F-FDG-PET/CT to Stage Patients With High-Risk Non-Muscle Invasive Bladder Cancer Before Radical Cystectomy.
- Published in:
- Clinical Genitourinary Cancer, 2023, v. 21, n. 3, p. 342, doi. 10.1016/j.clgc.2023.02.004
- By:
- Publication type:
- Article
3D-Reconstructed Contact Surface Area and Tumour Volume on Magnetic Resonance Imaging Improve the Prediction of Extraprostatic Extension of Prostate Cancer.
- Published in:
- Journal of Digital Imaging, 2023, v. 36, n. 2, p. 486, doi. 10.1007/s10278-022-00756-y
- By:
- Publication type:
- Article
Optimization and validation of <sup>18</sup>F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer.
- Published in:
- PLoS ONE, 2023, v. 18, n. 11, p. 1, doi. 10.1371/journal.pone.0293672
- By:
- Publication type:
- Article
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
The intra- and interobserver variability of PSMA-expression scores in patients with primary prostate cancer.
- Published in:
- EJNMMI Research, 2024, v. 14, n. 1, p. 1, doi. 10.1186/s13550-024-01152-z
- By:
- Publication type:
- Article
Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation.
- Published in:
- Clinical Epigenetics, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13148-022-01240-8
- By:
- Publication type:
- Article
Pathologic Features of Prostate Cancer Found at Population-Based Screening With a Four-Year Interval.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2001, v. 93, n. 16, p. 1153, doi. 10.1093/jnci/93.15.1153
- By:
- Publication type:
- Article
Pathologic Features of Prostate Cancer Found at Population-Based Screening With a Four-Year Interval.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2001, v. 93, n. 15, p. 1153, doi. 10.1093/jnci/93.15.1153
- By:
- Publication type:
- Article
Treating Primary Node-Positive Prostate Cancer: A Scoping Review of Available Treatment Options.
- Published in:
- Cancers, 2023, v. 15, n. 11, p. 2962, doi. 10.3390/cancers15112962
- By:
- Publication type:
- Article
Targeting PSMA Revolutionizes the Role of Nuclear Medicine in Diagnosis and Treatment of Prostate Cancer.
- Published in:
- Cancers, 2022, v. 14, n. 5, p. 1169, doi. 10.3390/cancers14051169
- By:
- Publication type:
- Article
Prostate Cancer Development Is Not Affected by Statin Use in Patients with Elevated PSA Levels.
- Published in:
- Cancers, 2019, v. 11, n. 7, p. 953, doi. 10.3390/cancers11070953
- By:
- Publication type:
- Article
Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case–control matching study.
- Published in:
- International Urology & Nephrology, 2022, v. 54, n. 12, p. 3145, doi. 10.1007/s11255-022-03339-6
- By:
- Publication type:
- Article
Clinical verification of <sup>18</sup>F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
- Published in:
- PLoS ONE, 2020, v. 15, n. 10, p. 1, doi. 10.1371/journal.pone.0239414
- By:
- Publication type:
- Article
Metastatic disease of screen-detected prostate cancer.
- Published in:
- Cancer (0008543X), 2006, v. 107, n. 12, p. 2779, doi. 10.1002/cncr.22374
- By:
- Publication type:
- Article
The predictive value for prostate cancer of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for prostate cancer.
- Published in:
- 2001
- By:
- Publication type:
- journal article
Selection of patients for nerve sparing surgery in robot‐assisted radical prostatectomy.
- Published in:
- BJUI Compass, 2022, v. 3, n. 1, p. 6, doi. 10.1002/bco2.115
- By:
- Publication type:
- Article
Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator.
- Published in:
- Therapeutic Advances in Urology, 2022, v. 14, p. 1, doi. 10.1177/17562872221088536
- By:
- Publication type:
- Article
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Staging prostate cancer.
- Published in:
- Microscopy Research & Technique, 2000, v. 51, n. 5, p. 423, doi. 10.1002/1097-0029(20001201)51:5<423::AID-JEMT4>3.0.CO;2-4
- By:
- Publication type:
- Article
A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.267260
- By:
- Publication type:
- Article
A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 6, p. 888, doi. 10.2967/jnumed.123.267260
- By:
- Publication type:
- Article
The Diagnostic Value of PSMA PET/CT in Men with Newly Diagnosed Unfavorable Intermediate-Risk Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 8, p. 1238, doi. 10.2967/jnumed.122.265205
- By:
- Publication type:
- Article
Reproducibility of PSMA PET/CT imaging for primary staging of treatment-naïve prostate cancer patients depends on the applied radiotracer: a retrospective study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263139
- By:
- Publication type:
- Article
Reproducibility of PSMA PET/CT imaging for primary staging of treatment-naïve prostate cancer patients depends on the applied radiotracer: a retrospective study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263139
- By:
- Publication type:
- Article
Standardized Uptake Values are Adequate Measures of Lesional <sup>18</sup>F‐DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.260232
- By:
- Publication type:
- Article
Standardized Uptake Values are Adequate Measures of Lesional <sup>18</sup>F‐DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.260232
- By:
- Publication type:
- Article
Standardized Uptake Values are Adequate Measures of Lesional <sup>18</sup>F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.260232
- By:
- Publication type:
- Article
Standardized Uptake Values are Adequate Measures of Lesional <sup>18</sup>F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.260232
- By:
- Publication type:
- Article
Standardized Uptake Values are Adequate Measures of Lesional <sup>18</sup>F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.260232
- By:
- Publication type:
- Article
Standardized Uptake Values are Adequate Measures of Lesional <sup>18</sup>F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.260232
- By:
- Publication type:
- Article
Standardized Uptake Values are Adequate Measures of Lesional <sup>18</sup>F‐DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 2, p. 1, doi. 10.2967/jnumed.120.260232
- By:
- Publication type:
- Article
Standardized Uptake Values are Adequate Measures of Lesional <sup>18</sup>F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 3, p. 1, doi. 10.2967/jnumed.120.260232
- By:
- Publication type:
- Article
Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.252528
- By:
- Publication type:
- Article
Repeatability of Quantitative <sup>18</sup>F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.119.236075
- By:
- Publication type:
- Article
Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.252528
- By:
- Publication type:
- Article
Repeatability of Quantitative <sup>18</sup>F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.119.236075
- By:
- Publication type:
- Article
Repeatability of Quantitative<sup> 18</sup>F‐DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 10, p. 1, doi. 10.2967/jnumed.119.236075
- By:
- Publication type:
- Article
Repeatability of Quantitative <sup>18</sup>F‐DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.119.236075
- By:
- Publication type:
- Article
Repeatability of Quantitative <sup>18</sup>F‐DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 8, p. 1, doi. 10.2967/jnumed.119.236075
- By:
- Publication type:
- Article
Repeatability of Quantitative <sup>18</sup>F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.119.236075
- By:
- Publication type:
- Article
Repeatability of Quantitative <sup>18</sup>F‐DCFPyL PET/CT Measurements in Metastatic Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.119.236075
- By:
- Publication type:
- Article